Trial Profile
Phase II trial of regorafenib in patients with imatinib resistrant gastrointestinal stromal tumor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms RESET for GIST
- 25 Jan 2020 Primary endpoint (Progression free survival rate at 24weeks) has not been met presented at the 2020 Gastrointestinal Cancers Symposium
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 07 Jan 2019 Status changed from active, no longer recruiting to completed.